Handelsbanken Fonder AB Purchases 700 Shares of Shockwave Medical, Inc. (NASDAQ:SWAV)

Handelsbanken Fonder AB boosted its stake in Shockwave Medical, Inc. (NASDAQ:SWAV) by 10.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 7,100 shares of the company’s stock after acquiring an additional 700 shares during the quarter. Handelsbanken Fonder AB’s holdings in Shockwave Medical were worth $1,353,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Lindbrook Capital LLC lifted its stake in Shockwave Medical by 64.8% in the 3rd quarter. Lindbrook Capital LLC now owns 150 shares of the company’s stock valued at $30,000 after purchasing an additional 59 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Shockwave Medical by 297.4% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 155 shares of the company’s stock valued at $31,000 after purchasing an additional 116 shares during the last quarter. Asset Management One Co. Ltd. bought a new position in Shockwave Medical in the 4th quarter valued at approximately $34,000. Operose Advisors LLC bought a new position in Shockwave Medical in the 3rd quarter valued at approximately $49,000. Finally, Venturi Wealth Management LLC bought a new position in Shockwave Medical in the 3rd quarter valued at approximately $82,000. Institutional investors own 95.35% of the company’s stock.

Insider Buying and Selling

In related news, CFO Dan Puckett sold 3,406 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $229.76, for a total transaction of $782,562.56. Following the transaction, the chief financial officer now directly owns 27,732 shares of the company’s stock, valued at $6,371,704.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CFO Dan Puckett sold 3,406 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $229.76, for a total transaction of $782,562.56. Following the transaction, the chief financial officer now directly owns 27,732 shares of the company’s stock, valued at $6,371,704.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Frank T. Watkins sold 2,000 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $231.76, for a total transaction of $463,520.00. Following the transaction, the director now directly owns 4,532 shares in the company, valued at $1,050,336.32. The disclosure for this sale can be found here. Insiders have sold a total of 89,813 shares of company stock valued at $22,863,919 over the last ninety days. 3.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on SWAV shares. CL King reissued a “neutral” rating on shares of Shockwave Medical in a research note on Monday, April 8th. Piper Sandler upped their price target on shares of Shockwave Medical from $290.00 to $360.00 and gave the company an “overweight” rating in a research report on Tuesday, April 2nd. Wolfe Research restated a “peer perform” rating on shares of Shockwave Medical in a research report on Friday, April 5th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $335.00 price target (up from $270.00) on shares of Shockwave Medical in a research report on Monday, April 8th. Finally, Needham & Company LLC restated a “hold” rating on shares of Shockwave Medical in a research report on Friday, April 5th. Ten equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $309.11.

Shockwave Medical Trading Up 0.3 %

SWAV opened at $330.00 on Friday. Shockwave Medical, Inc. has a twelve month low of $157.00 and a twelve month high of $331.58. The company has a quick ratio of 10.73, a current ratio of 11.76 and a debt-to-equity ratio of 1.09. The company has a fifty day moving average of $294.88 and a 200-day moving average of $233.41. The stock has a market cap of $12.34 billion, a PE ratio of 85.27, a price-to-earnings-growth ratio of 2.45 and a beta of 0.92.

Shockwave Medical (NASDAQ:SWAV) last posted its quarterly earnings data on Thursday, February 15th. The company reported $1.16 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.24. Shockwave Medical had a net margin of 20.17% and a return on equity of 23.97%. The company had revenue of $202.98 million during the quarter, compared to analysts’ expectations of $199.43 million. During the same period in the prior year, the company posted $3.71 earnings per share. Shockwave Medical’s revenue for the quarter was up 41.0% compared to the same quarter last year. On average, sell-side analysts predict that Shockwave Medical, Inc. will post 4.94 EPS for the current year.

Shockwave Medical Company Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.